We are recruiting a postdoctoral researcher in the field of medicinal chemistry/cancer drug discovery

We are looking for an ambitious and creative medicinal chemist to lead drug discovery projects targeting novel anti-cancer drug targets. This is a full-time 24-month CDD, with the possibility of extension. There is a flexible start in mid to late 2022 and you will be based at White City Campus.

You will join a team of researchers at the state-of-the-art £170 million Molecular Sciences Research Center at Imperial’s new White City campus, applying cutting-edge structure-guided drug discovery against critical cancer signaling pathways. Our projects are bolstered by several new series of hits/leads, an extensive suite of established biochemical and cellular assays, and a unique structural biology platform, supported by collaborations with scientists from the University of Oxford, Cancer Research Institute and our laboratory at the Francis Crick Institute. We have assembled a team of exceptional scientists including medicinal chemists, experts in cell and molecular biology, structural biology and pharmacology, positioning these programs to progress rapidly towards in vivo proof-of-concept studies. See the Tate Group website for examples: Mol. Cell. 2021, 5025; Angelw. Chemistry. 2021, 13542; JAC 2020, 12020; RSC Med. Chem. 2022, 13, 150. Further details will be discussed confidentially with shortlisted candidates.

For any informal inquiries regarding the position, please contact Professor Ed Tate: ([email protected])

Applications should be submitted through the portal, where further information can also be found.